ArticleMolecular cytogenetics2026
Cytogenetic patterns of hematologic malignancies before, during and after the COVID-19 pandemic: a single-center retrospective study in Thailand.
Article in Molecular cytogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematologic malignancies frequently harbor recurrent cytogenetic abnormalities that are essential for diagnosis and prognostic stratification. The COVID-19 pandemic raised concerns that infection-related biological effects or disruptions in healthcare deliverymight influence the frequency or distribution of these abnormalities.
objectiveTo evaluate whether the COVID-19 pandemic was associated with changes in the frequency of chromosomal abnormalities detected in hematologic malignancies.
methodsWe retrospectively analyzed 3,162 bone marrow samples referred for cytogenetic testing between 2018 and 2024 at a tertiary center in Thailand. Cases were categorized into Pre-COVID (2018-2019), Peak COVID (2020-2021), and Post-COVID (2022-2024) periods. Proportions of abnormal karyotypes and recurrent cytogenetic lesions were compared using risk ratios with 95% confidence intervals and two-proportion z-tests.
resultsOverall proportions of abnormal karyotypes remained largely stable across pandemic periods. In AML, complex karyotypes (10-16%) were consistent with previously reported ranges, whereas balanced translocations such as t(15;17), t(8;21), and inv(16) occurred less frequently than reported in large international cohorts. In MDS, recurrent abnormalities including del(5q), del(20q), and complex karyotypes were underrepresented relative to published literature. In ALL, the proportion of abnormal karyotypes declined during the Peak COVID period (20.7% vs. 44.4% in the Pre-COVID period, p = 0.01) but returned to baseline levels thereafter. CLL showed a marked reduction in abnormal karyotypes during the Post-COVID period (5.7% vs. 40.0% Pre-COVID, p < 0.001). No significant temporal changes were observed in MM, MPN, or lymphoma.
conclusionsThe overall cytogenetic landscape of hematologic malignancies remained largely stable throughout the COVID-19 pandemic. Observed variations in ALL and CLL are more likely related to changes in healthcare access or referral patterns rather than direct biological effects of SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.